Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic…
Triplet chemotherapy (FOLFOXIRI) + bevacizumab regimen is indicated as first-line treatment of BRAF-mutated metastatic colorectal cancer (mCRC).
- Ref: Clin Nucl Med. 2020 Sep;45(9):707-708.
- Année de publication : 2020
- Auteurs : Amrane K, le Pennec R, Schick U, Metges JP, Abgral R.
- Réseaux : Réseaux: « Vectorisation, Imagerie, Radiothérapies »